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Abstract
Objective—To examine the association between neuropsychiatric (NP) events with 
antiphospholipid antibodies (lupus anticoagulant, anticardiolipin), anti-β2 glycoprotein-I, anti-
ribosomal P and anti-NR2 glutamate receptor antibodies in an international inception cohort.
Methods—NP events were identified using the ACR case definitions and clustered into central/
peripheral and diffuse/focal events. Attribution of NP events was determined using decision rules 
of different stringency (model A and model B). Autoantibodies were measured without knowledge 
of NP events or their attribution.
Results—412 patients (87.3% female; mean (± SD) age of 34.9 ± 13.5 years; mean disease 
duration 5.0 ± 4.2 months) were studied. There were 214 NP events in 133 (32.3%) patients. NP 
events attributed to SLE varied from 15% (model A) to 36% (model B). There was no association 
between autoantibodies and NP events from all causes. However the frequency of anti-ribosomal P 
antibodies in patients with NP events due to SLE (model A) was 4/24 (16.6%) compared to 3/109 
(2.8%) for all other NP events and 24/279 (8.6%) with no NP events (P=0.07). Furthermore anti-
ribosomal P antibodies in patients with central NP events attributed to SLE (model A) was 4/20 
(20%) vs. 3/107 (2.8%) for other NP events and 24/279 (8.6%) with no NP events (P = 0.04). For 
diffuse NP events the antibody frequencies were 3/11 (27%) compared to 4/111 (3.6%) and 24/279 
(8.6%) respectively (P=0.02).
Conclusion—NP events at onset of SLE were associated with anti-ribosomal P antibodies, 
suggesting a pathogenetic role for this autoantibody. There was no association with other 
autoantibodies.
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Neurological and psychiatric events are well described in patients with systemic lupus 
erythematosus (SLE). The frequency of neuropsychiatric (NP) disease, classified using the 
ACR case definitions, varies from 37% to 95% of patients (1–5). The clinical significance of 
NP events is underlined by the negative impact on health-related quality of life (3, 6) and 
increased mortality (7). Determining the correct attribution of NP events is a significant 
challenge when dealing with nervous system disease in individual SLE patients and is a 
critical factor in selecting the correct treatment and determining prognosis. To date there are 
no reliable biomarkers which can be used to make this decision.
Lupus specific mechanisms underlying NP disease include vasculopathy of intracranial 
vessels, local or systemic production of inflammatory mediators and the generation of 
specific autoantibodies (8–11). The latter include antiphospholipid antibodies, anti-
ribosomal P antibodies and autoantibodies which bind to neuronal antigens such as the 
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recently described antibodies to the NR2 glutamate receptor (12). Although there is 
biological plausibility and data from in vitro studies and animal studies (12–16) to implicate 
these autoantibodies in the causality of nervous system disease, studies of human SLE have 
provided inconsistent findings (17–21). Previous efforts have been limited by their cross-
sectional study design, the inclusion of patients with variable disease duration, and lack of 
standardization in both the classification of NP events and the methodology used for 
autoantibody detection. Thus, in the current study we have assembled an international, 
inception cohort of SLE patients to examine the association between a panel of 
autoantibodies and nervous system events at the time of diagnosis of SLE.
Patients and Methods
Research study network
The study was conducted by members of the Systemic Lupus International Collaborating 
Clinics (SLICC) (22) which consists of 30 investigators in 27 international academic 
medical centres. Data were collected prospectively on patients presenting with a new 
diagnosis of SLE. All information was submitted to the coordinating centre in Halifax, Nova 
Scotia, Canada and entered into a centralized Access database. Appropriate procedures were 
instituted to ensure data quality, management and security. Additional information on the 
same patients was collected concurrently as part of a study examining atherosclerosis in SLE 
and submitted to the coordinating centre for that study at the University of Toronto, Ontario, 
Canada. Electronic data transfer occurred between the Toronto and Halifax sites and the 
merged datasets were available for analyses. The study protocol was approved by the Capital 
Health Research Ethics Board, Halifax, Nova Scotia, Canada and by each of the 
participating centre’s own institutional research ethics review boards.
Patients
All patients fulfilled four or more of the ACR classification criteria for SLE (23) and 
provided written informed consent. The date of diagnosis was taken as the time when these 
cumulative criteria were first recognized. Enrollment in the study was encouraged as close as 
possible to the date of diagnosis but was permitted for up to 15 months following the 
diagnosis. Variables which were collected included age, gender, ethnicity, education and 
medication history. Lupus-related variables included the ACR classification criteria for SLE 
(23), the SLE Disease Activity Index (SLEDAI) (24) and the SLICC/ACR damage index 
(SDI) (25) in patients whose disease duration was six months or longer. Routine laboratory 
variables included hematology, serum and urine chemistry and immunologic variables 
required for the generation of SLEDAI and SDI scores.
Neuropsychiatric (NP) events
An enrollment window was defined within which all NP events, some of which are 
inherently evanescent, were captured. To ensure inclusion of NP events which may have 
been a component of the presentation of lupus but which occurred prior to the accumulation 
of four ACR classification criteria, the enrollment window extended from 6 months prior to 
the date of diagnosis of SLE up to the enrollment date. As the latter could occur up to 15 
months following the diagnosis of SLE, the maximum duration of the enrollment window 
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was 21 months. The specific NP events which were identified within this time frame were 
based upon the ACR nomenclature and case definitions for 19 NP syndromes (26) described 
in SLE. Screening for all NP syndromes was done primarily by clinical evaluation and 
subsequent investigations were performed only if clinically warranted. In order to further 
improve the consistency of data collection, a checklist of NP symptoms was distributed to 
each of the participating sites for use during patient encounters. In the majority of cases, the 
diagnosis of cognitive impairment was made on the basis of clinical assessment rather than 
formal neuropsychological testing. The eight cognitive domains which were assessed were 
Simple attention, Complex attention, Memory, Visual-Spatial processing, Language, 
Reasoning/problem solving, Psychomotor speed and Executive functions.
The occurrence of all NP events within the enrollment window was identified and additional 
information was recorded. The specific information depended upon the type of NP event and 
was guided by the ACR glossary for the 19 NP syndromes (26). This included a list of 
potential etiologic factors other than SLE which were identified for exclusion, or recognized 
as an “association”, acknowledging that in some situations it is not possible to be definitive 
about attribution. Collectively, these “exclusions” and “associations” were referred to as 
“non-SLE factors” and were used in part to determine the eventual attribution of NP events. 
Patients could have more than one type of NP event but repeated episodes of the same NP 
event occurring within the enrollment window were recorded only once. In the latter case the 
time of the first episode was taken as the date of onset of the NP event.
Attribution of NP events
Participating centres were asked to report all NP events regardless of etiology and in 
particular no NP events were excluded on the basis that an individual investigator felt that 
these were not attributable to SLE. Decision rules were derived to determine the attribution 
of NP events which occurred within the enrollment window. Factors which were considered 
included: (i) onset of NP event(s) prior to the enrollment window; (ii) presence of concurrent 
non-SLE factor(s) which were identified as part of the ACR definitions for each NP 
syndrome and considered to be a likely cause or significant contributor to the event; (iii) 
occurrence of "minor” NP events as defined by Ainiala et al who have previously reported 
such events in a high frequency of normal population controls (1). These latter NP 
manifestations include all headaches, anxiety, mild depression (i.e. all mood disorders which 
fail to meet the criteria for “major depressive-like episodes”), mild cognitive impairment 
(deficits in less than 3 of the 8 specified cognitive domains) and polyneuropathy without 
electrophysiological confirmation.
The attribution of NP events to SLE and non-SLE causes was determined by two sets of 
decision rules of different stringency as described in detail elsewhere (6):
Attribution Model A: NP events which had their onset prior to the enrollment 
window or had at least one “exclusion” or “association” or were one of the NP events 
identified by Ainiala (1) were attributed to a non-SLE etiology.
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Attribution Model B: NP events which had their onset at least 10 years prior to the 
diagnosis of SLE or had at least one “exclusion” or were one of the NP events 
identified by Ainiala (1) were attributed to a non-SLE etiology.
Determination of autoantibodies
Serum samples were collected within 5.3 ± 17.1 days (mean ± SD) days of the enrollment 
date. Autoantibodies, with the exception of anti-dsDNA antibodies, were measured in Dr. 
Joan Merrill’s laboratory at the Oklahoma Medical Research Foundation, USA. 
Autoantibody determinations were made without knowledge of the occurrence of NP events 
or their attribution in individual patients.
ELISA for anti-NR2 antibodies—NR2 human peptide sequence, (Asp Trp Glu Tyr Ser 
Val Trp Leu Ser Asn)8 Lys 4 Lys2 Lys-β Ala, was synthesized using f-moc chemistry, 
purified by HPLC and confirmed by Edman degradation at the Molecular Biology 
Proteomics Facility of the University of Oklahoma Health Sciences Center, Oklahoma City, 
OK. High binding, Nunc 96-well polystyrene plates were coated with 5 ug/mL of NR2 
peptide in borate buffered saline and blocked with borate buffered saline, bovine serum 
albumin (Fraction V, Sigma) and 1.2% Tween 80. Patient sera, positive and negative controls 
were added, diluted 1/100 in the same blocking buffer. Plates were washed with borate 
buffered saline between each step with vigorous pounding to eliminate non-specific binding. 
Secondary antibody was an alkaline phosphatase conjugated goat anti-human IgG (Sigma) 
with the addition of goat serum to block non-specific binding (doner herd, Sigma). Plates 
were developed using p-NPP substrate buffer (Sigma). Optical density of the enzyme-linked 
immune assay were read at 405 (primary wavelength) and 450 (secondary wavelength). 
Serial dilutions of a high binding positive control were used as a calibrator.
Antiphosphilipid and anti-ribosomal P antibodies—Lupus anticoagulant and 
ELISAs for anticardiolipin, anti-β2 glycoprotein-I and anti- ribosomal P protein were 
performed as previously described (27–29). β2 glycoprotein-I, purified from human plasma, 
was the gift of Drs. Naomi and Charles Esmon, and ribosomal P protein was provided by the 
laboratory of Dr. Morris Reichlin, Oklahoma Medical Research Foundation.
Anti-dsDNA antibodies—Anti-dsDNA antibodies were measured at each of the 
participating SLICC centers and reported as positive or negative according to the centers 
specific normal range.
Statistical analysis
Individual NP manifestations were categorized by attribution to SLE (model A or model B) 
or non-SLE causes. The distribution of patients in this hierarchy, and a no NP event class, 
was examined for associations with different autoantibodies. In addition the NP 
manifestations were clustered into subgroups for additional analyses of clinical-serologic 
associations. Thus, the 19 NP syndromes were arranged into central and peripheral nervous 
system manifestations as previously described (26). Diffuse NP syndromes were identified 
as aseptic meningitis, demyelinating syndrome, headache, acute confusional state, anxiety 
disorder, cognitive dysfunction, mood disorder and psychosis. Focal NP syndromes were 
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cerebrovascular disease, Guillain Barré syndrome, movement disorder, myelopathy, seizure 
disorders, autonomic neuropathy, mononeuropathy, myasthenia gravis, cranial neuropathy, 
plexopathy and polyneuropathy. In view of previously reported clinical-serologic 
correlations the following associations were also specifically examined: (i) lupus 
anticoagulant, anticardiolipin and anti-β2-GPI with cerebrovascular disease, seizure 
disorders, demyelinating syndrome and movement disorder; (ii) anti-ribosomal P and anti-
NR2 with mood disorder, cognitive impairment and psychosis. Reported significance levels 
are based on χ2 tests, or Fisher’s exact test, as appropriate.
Results
Patients
A total of 412 patients were recruited in 18 centres between October 1999 and April 2005. 
The median (range) number of patients enrolled in each centre was 13 (3–56). The patients 
were predominantly women, with a mean (± SD) age of 34.9 ± 13.5 years and a wide ethnic 
distribution although predominantly Caucasian (Table 1). At enrollment the mean disease 
duration was only 5 ± 4.2 months despite the opportunity to recruit patients up to 15 months 
following the diagnosis of SLE. The prevalence of individual ACR classification criteria 
reflected an unselected patient population. The mean SLEDAI and SDI scores revealed 
moderate global disease activity and minimal cumulative organ damage respectively. 
Therapy at the time of enrollment reflected the typical range of lupus medications.
Neuropsychiatric (NP) manifestations
Within the enrollment window 133/412 (32.3%) patients had at least 1 NP event and 47/412 
(11.4%) had 2 or more events with a maximum of 7 events. The NP events and their 
attribution are summarized in Table 2. There were a total of 214NP events, encompassing 14 
of the 19 NP syndromes: headache (40.2%), mood disorders (14.9%), anxiety disorder 
(7.9%), cerebrovascular disease (6.5%), cognitive dysfunction (6.5%), acute confusional 
state (5.1%), seizure disorders (5.1%), polyneuropathy (3.7 %), psychosis (3.3%), 
mononeuropathy (2.8%), cranial neuropathy (1.9%), aseptic meningitis (0.9%), myelopathy 
(0.5%) and movement disorder (0.5%). The proportion of NP events attributed to SLE varied 
from 15% – 36% using alternate attribution models and occurred in 5.8 % [model A] – 
12.9 % [model B] of patients. There were no patients with autonomic disorder, Guillain-
Barré syndrome, demyelinating syndrome, myasthenia gravis or plexopathy. Of the 214 NP 
events 196 (91.6 %) affected the central nervous system and 18 (8.4%) involved the 
peripheral nervous system. The classification of events into diffuse and focal was 169 
(79.0%) and 45 (21.0 %), respectively.
Autoantibodies and NP events
The overall prevalence of the different autoantibodies within the inception cohort is 
illustrated in Figure 1. This varied from 8% for anti-ribosomal P antibodies to 45% for anti-
DNA antibodies. There was no significant association between the frequency of 
autoantibodies in patients with and without NP events due to any cause (Figure 1). In fact 
the prevalence of autoantibodies was usually higher in patients without NP events although 
this did not reach statistical significance.
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The NP events were then classified by attribution to determine if this would provide a 
stronger correlation with specific autoantibodies. Four mutually exclusive groups were 
examined: patients with NP events attributed to SLE who qualify under model A (NP-SLE 
(A)), patients with NP events attributed to SLE who qualify under model B but not model A 
(NP-SLE (B not A)), patients with NP events attributed to non-SLE causes (NP (non-SLE)) 
and patients with no NP events (No NP events)(Figure 2). In this analysis the only clinical-
serologic association that approached significance was between NP events attributed to SLE 
and anti-ribosomal P antibodies (P = 0.07). The frequency of anti-ribosomal P antibodies in 
patients with NP events due to SLE determined using the most stringent of the two 
attribution models (model A) was 4/24 (16.6%) compared to 3/109 (2.8%) for patients with 
all other NP events and 24/279 (8.6%) in patients with no NP events. The specific events in 
the 4 patients with anti-ribosomal P antibodies and NP events attributed to SLE (model A) 
were psychosis only (1 patient), psychosis and cognitive dysfunction (1 patient), acute 
confusional state, myelopathy and mononeuropathy (1 patient) and cerebrovascular disease 
(1 patient). Stronger associations for anti-ribosomal P antibodies and NP events attributed to 
SLE (model A) were observed with central (P = 0.04) and diffuse (P=0.02) NP events 
(Figure 3). Thus for central NP events the frequency of anti-ribosomal P antibodies in 
patients with NP events attributed to SLE (model A) was 4/20 (20%) compared to 3/107 
(2.8%) for patients with all other central NP events and 24/279 (8.6%) in patients with no 
NP events. For diffuse NP events the antibody frequencies were 3/11 (27%) compared to 
4/111 (3.6%) and 24/279 (8.6%) respectively. Significant differential effects between 
central/peripheral and diffuse/focal classifications could not be detected with the small 
number of cases available.
Analyses were also performed to examine specific a priori clinical-serologic associations. 
The power of these analyses are limited due to small numbers of cases but no associations 
could be demonstrated between lupus anticoagulant, anticardiolipin and anti-β2-GPI 
antibodies with cerebrovascular disease, seizure disorders, demyelinating syndrome or 
movement disorder. Similarly there was no demonstrable association between anti-NR2 
antibodies with mood disorder or cognitive dysfunction.
Seven patients had psychosis which was attributed to SLE. This attribution was made in 3 
patients using model A and in an additional 4 patients using model B. Two of the 3 patients 
in model A and 1 of the 4 patients in model B had anti-ribosomal P antibodies. The latter 
patient was not included under model A due to the fact that corticosteroids were identified as 
a potential contributing factor to the patient’s psychosis and thus recognized as an 
“association” as per the ACR case definition for psychosis (26). While the frequency of anti-
ribosomal P antibodies in patients with psychosis (model A) compared to patients with no 
NP events achieved statistical significance (P = 0.02), the inclusion of this latter patient as an 
NP model A event, achieves a significance level of P = 0.003. Although some caution must 
be exercised in interpreting this finding, it indicates the importance of psychosis in 
explaining the observed association of anti-ribosomal P antibodies with NP events attributed 
to SLE.
Hanly et al. Page 7




















Several autoimmune and inflammatory mechanisms likely play a role in the pathogenesis of 
NP-SLE (8–11). Current data suggests that antiphospholipid antibodies as measured by 
lupus anticoagulant, anticardiolipin and anti-β2-GPI antibodies cause focal NP disease (e.g. 
stroke, seizures) by promoting intra-vascular thrombosis. In contrast, anti-ribosomal P and 
possibly anti-NR2 antibodies cause diffuse NP events (e.g. psychosis, depression, cognitive 
impairment) through a direct effect on neuronal cells. A critical factor for the second group 
of autoantibodies is the ability to directly access neuronal cells either through the intra-
thecal production of autoantibodies or their passage from the circulation across a 
permeablilized blood-brain-barrier.
The most direct evidence supporting the autoantibody hypothesis of NP-SLE is derived from 
studies of animal models (12–16) but the evidence from human studies is frequently 
conflicting or inconclusive (17–21). This may be due in part to methodological difficulties 
such as selection of patients for study, a lack of rigor in the characterization of NP events 
and inter-laboratory differences in assay technique. Thus we constituted an international 
disease inception cohort of SLE patients utilizing a standardized approach for the 
characterization of NP events and determining their attribution. Our primary objective was to 
examine the association between a panel of specific autoantibodies and NP-SLE events 
occurring around the time of diagnosis of SLE. In our data, only anti-ribosomal P antibodies 
provided any evidence of an association with NP events attributed to SLE.
The measurement of autoantibodies of interest to NP-SLE was performed in a single centre 
with expertise in autoantibody detection in order to avoid variability in laboratory 
methodology. In general the prevalence of autoantibodies was lower than that reported in 
other lupus cohorts. Thus, the frequency of lupus anticoagulant, anticardiolipin, anti-β2-GPI, 
anti-ribosomal P and anti-NR2 antibodies was 18%, 18%, 16%, 8% and 19% respectively, 
which is lower than that reported in previous studies of SLE patients where, for example, the 
prevalence was 34% (30), 44% (30), 20% (31), 17% (20) and 35% (19), respectively. 
However, ours is the first study to measure this complete panel of autoantibodies in a disease 
inception cohort which in combination with our efforts to minimize non-specific antibody 
binding is probably the explanation for the lower prevalence rates. With further followup the 
frequency of all autoantibodies in this patient cohort will very likely increase in keeping 
with previous longitudinal studies of SLE patients(32).
In the present study only anti-ribosomal P antibodies demonstrated any association with NP 
events attributed to SLE. The decision rules for attribution were clinically based and did not 
include information of autoantibody status. Thus, the highest frequency of anti-ribosomal P 
autoantibodies occurred in patients with NP events attributed to SLE, as defined using the 
most stringent of the attribution rules. These findings provide support for the possible role of 
anti-ribosomal P antibodies in NP-SLE. However, in keeping with the findings of a recent 
metanalysis (21) the low sensitivity limits the utility of the test which cannot be used in 
isolation as a reliable biomarker to determine the attribution of NP events. None of the other 
autoantibodies demonstrated an association with NP-SLE and in particular anticardiolipin 
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antibodies demonstrated a negative association with NP-SLE although this did not reach 
statistical significance.
There are a number of limitations to our study. First, due to the lack of specificity of most of 
the NP events, composite arbitrary decision rules were developed as previously described 
(6). However, in the case of anti-ribosomal P antibody which was the only autoantibody for 
which there was a significant association with NP-SLE events, the pattern of the association 
indicated an effect in favour of NP events attributed to SLE. Second, although our disease 
inception cohort was of reasonable size, many of the individual NP events attributed to SLE 
were infrequent which limited the statistical power of the analysis. Third, as autoantibodies 
were determined at a single time point it is possible the some patients with an evanescent 
pattern of autoantibody production could have been overlooked. Finally, the study did not 
address whether autoantibodies were present within the intra-thecal space by sampling 
cerebrospinal fluid or using a circulating biomarker of blood-brain-barrier permeability.
Despite these limitations our study provides novel information on the prevalence of this 
unique panel of autoantibodies in an international inception cohort and found an association 
between NP-SLE events with anti-ribosomal P antibodies. Future studies will determine the 
reproducibility of this finding in an expanded disease inception cohort and whether any of 
these autoantibodies predict the subsequent development or course of NP events over time.
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Frequency of autoantibodies in SLE inception cohort. The upper panel illustrates the 
proportion of all SLE patients with autoantibodies and the lower panel illustrates the 
frequency of autoantibodies in patients with and without neuropsychiatric (NP) events from 
all causes.
LA = lupus anticoagulant; aCL = IgG anticardiolipin antibody; aBeta-2 = anti-β2-
glycoprotein I; anti-P = anti-ribosomal P antibody; aNR2 = anti-NR2 glutamate receptor 
antibody; aDNA = anti-DNA antibody.
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The frequency of autoantibodies in SLE patients with and without neuropsychiatric (NP) 
events. Four mutually exclusive groups were examined: patients with NP events attributed to 
SLE who qualify under model A (NP-SLE (A)), patients with NP events attributed to SLE 
who qualify under model B but not model A (NP-SLE (B not A)), patients with NP events 
attributed to non-SLE causes (NP (non-SLE)) and patients with no NP events (No NP 
events).
Model A: The onset of NP events prior to the enrollment window, the identification of any 
non-SLE factors which contributed to or were responsible for the NP event or the occurrence 
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of a “minor” NP event as defined by Ainiala et al (1) indicated that the NP event was not 
attributed to SLE.
Model B: The onset of NP events more than 10 years prior to the diagnosis of SLE, the 
identification of non-SLE factors which were responsible for the NP event (“exclusion 
factors” only) or the occurrence of a “minor” NP event as defined by Ainiala et al (1) 
indicated that the NP event was not attributed to SLE.
LA = lupus anticoagulant; aCL = IgG anticardiolipin antibody; aBeta-2 = anti-β2- 
glycoprotein I; anti-P = anti-ribosomal P antibody; aNR2 = anti-NR2 glutamate receptor 
antibody; aDNA = anti-DNA antibody.
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The frequency of anti-ribosomal P antibodies in SLE patients with and without central 
(upper panel) and diffuse (lower panel) neuropsychiatric (NP) events. Central NP 
manifestations have been previously described (26). Diffuse NP syndromes were identified 
as aseptic meningitis, demyelinating syndrome, headache, acute confusional state, anxiety 
disorder, cognitive dysfunction, mood disorder and psychosis.
Four mutually exclusive groups were examined: patients with NP events attributed to SLE 
who qualify under model A (NP-SLE (A)), patients with NP events attributed to SLE who 
qualify under model B but not model A (NP-SLE (B not A)), patients with NP events 
attributed to non-SLE causes (NP (non-SLE)) and patients with no NP events (No NP 
events).
Model A: The onset of NP events prior to the enrollment window, the identification of any 
non-SLE factors which contributed to or were responsible for the NP event or the occurrence 
of a “minor” NP event as defined by Ainiala et al (1) indicated that the NP event was not 
attributed to SLE.
Model B: The onset of NP events more than 10 years prior to the diagnosis of SLE, the 
identification of non-SLE factors which were responsible for the NP event (“exclusion 
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factors” only) or the occurrence of a “minor” NP event as defined by Ainiala et al (1) 
indicated that the NP event was not attributed to SLE.
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Table 1
Demographic and clinical manifestations of SLE patients
Number of Patients 412
Gender
 Female 357 (87.3%)
 Male 52 (12.7%)
Age (years) (mean ± SD) 34.9 (13.5)
Ethnicity:
 Caucasian 255 (62.5%)
 Hispanic 12 (2.9%)
 Asian 70 (17.2%)
 Black 56 (13.7%)
 Other 15 (3.7%)
Single/Married/Other 177 (43.3%)/168 (41.1%)/64 (15.6)
Post secondary education 273 (66.75%)
Disease duration (months) (mean ± SD) 5.0 ± 4.2
Number of ACR criteria (mean ± SD) 4.9 ± 1.0
Cumulative ACR manifestations
 Malar rash 138 (33.7%)
 Discoid rash 46 (11.2%)
 Photosensitivity 146(35.7 %)
 Oral/nasopharyngeal ulcers 111 (27.1%)
 Serositis 306 (74.8%)
 Arthritis 161 (39.4%)
 Renal disorder 107 (26.2%)
 Neurological disorder 22 (5.4%)
 Hematologic disorder 251 (61.4%)
 Immunologic disorder 313 (76.5%)
 Antinuclear antibody 401 (98.0%)
SLEDAI score (mean ± SD) 6.1 ± 5.9
SLICC/ACR damage index score (mean ± SD) 0.32 ± 0.7
Medications
 Corticosteroids 267 (65.3%)
 Antimalarials 256 (63.2%)
 Immunosuppressants 149 (36.9%)
 ASA 61 (15.0%)
 Antidepressants 40 (9.8%)
 Anticonvulsants 18 (4.4%)
 Warfarin 18 (4.4%)
 Antipsychotics 3 (0.7%)
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